GERN
$1.62
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
Intraday
Recent News
Geron Details RYTELO Growth Plan, $220M-$240M 2026 Sales Guide and MF Trial Catalyst at Barclays Conference
Executives from Geron (NASDAQ:GERN) outlined their commercial priorities for RYTELO (imetelstat) and provided updates on the company’s pipeline and financial outlook during a discussion hosted by Barclays. Leadership says commercial plan is being refined as RYTELO enters second year Harout Semerjia
Geron Corporation (GERN) Reports Q4 EPS of (5c)
Geron Corporation (NASDAQ:GERN) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On February 25, 2026, Geron Corporation (NASDAQ:GERN) reported fourth-quarter EPS of (5c), compared with consensus estimates of (4c), and revenue of $48M versus consensus of $50.43M. CEO Harout Semerjian said strategic actions taken in the second half of 2025 were […]
How The Geron (GERN) Story Is Shifting After Target Cut And New Equity Plans
Geron is back in focus after analysts trimmed their price target by US$1, while the model fair value estimate holds steady at US$3.40. Some on the Street see the change as a reset of expectations, others view it as a signal that prior assumptions may have been set too high, and both camps are watching how the story develops from here. As you read on, you will see how this updated target fits into the broader narrative and what to watch as sentiment around Geron evolves. Stay updated as the...
Is Geron (GERN) Using Its New ATM Program To Prioritize Flexibility Over Shareholder Dilution?
In early March 2026, Geron Corporation filed a universal shelf registration covering common stock, preferred stock, debt securities and warrants, and registered an at-the-market follow-on equity offering of up to US$150 million in common stock. This move materially expands Geron’s financing flexibility, highlighting management’s focus on securing capital to support ongoing operations and potential growth initiatives while raising questions about future dilution for existing...
Geron (GERN) 2025 Revenue Surges to $183.6M Driven by RYTELO Commercial Success
Geron Corporation (NASDAQ:GERN) is one of the most promising penny stocks under $5 to buy. On February 25, Geron Corporation reported earnings results for Q4 and the full year of 2025, fueled by the commercial success of its first-in-class telomerase inhibitor, RYTELO. The company achieved $48 million in net product revenue for Q4 and $183.6 […]